Renal Cell Carcinoma – Geographic Focus: China – China In-Depth – Renal Cell Carcinoma
The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient, Amgen’s Nexavar) and mTOR inhibitors (Novartis’s Afinitor). In June 2023, Shanghai Junshi Biosciences’ PD-1 inhibitor Tuoyi (plus Inlyta) became the first immune checkpoint inhibitor to enter this market. We anticipate that China’s RCC therapy market will further expand over the 2023-2033 forecast period. Key market drivers include the continued uptake of targeted therapies for metastatic disease, the launch of novel drugs and/or combinations (e.g., MET inhibitors, triplet combinations containing immune checkpoint inhibitors and TKIs), and the launch of targeted treatments in the early-stage setting. In this report, we assess how clinical and nonclinical factors (e.g., inclusion in China’s National Reimbursement Drug List) will influence the launch and uptake of new therapies during the forecast period. Understanding the impact of these intersecting factors will be key to current and future players’ success in this highly lucrative market.
Questions answered
- What is the diagnosed incidence of RCC, and how are these patients treated today? Do treatment management strategies differ between urban and rural China?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of RCC?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content highlights
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists; supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed incidence of RCC in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key RCC therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions
Emerging therapies: Phase 3/ PR: 5+ regimens
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
